Alan Epstein, MD
Rheumatology · Philadelphia, PANPI 1346211844
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $797,701 of the $1,157,601 with a category attached, or 68.9%. It is spread thinly across 30 manufacturers, the largest accounting for just 17.2%. Reporting peaked in 2019 at $335,476 and has fallen 85.6% since, to $48,294 in 2025. Among rheumatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,551 payments — averaging $746.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$199K
- AbbVie$179K
- Lilly USA, LLC$164K
- Amgen$109K
- AstraZeneca$97K
- GSK$70K
- plus $340K from 24 others
Across 3 payments — averaging $545.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$217,40019%
- Speaking & faculty fees$797,70169%
- Travel & lodging$115,04210%
- Food & beverage$27,1482%
- Education$3090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 128 | $198,915 |
| AbbVie | 293 | $179,106 |
| Lilly USA, LLC | 289 | $163,762 |
| Amgen(2 entities) | 201 | $108,676 |
| AstraZeneca(2 entities) | 126 | $97,163 |
| GSK | 68 | $69,703 |
| Regeneron Healthcare Solutions, Inc. | 78 | $62,711 |
| Johnson & Johnson(2 entities) | 82 | $61,404 |
| Janssen Scientific Affairs, LLC | 58 | $57,867 |
| Pfizer | 73 | $38,672 |
| Novartis | 32 | $30,328 |
| United Rheumatology | 5 | $28,900 |
| E.r. Squibb & Sons, L.L.C. | 42 | $24,248 |
| Sandoz | 6 | $9,751 |
| Fresenius Kabi USA, LLC | 3 | $6,925 |
| Gilead | 10 | $5,643 |
| UCB, Inc. | 21 | $5,094 |
| Sobi, Inc | 4 | $2,810 |
| Boehringer Ingelheim | 5 | $2,232 |
| Invivyd Inc | 1 | $2,013 |
| Eli Lilly | 2 | $775 |
| Aurinia Pharma U.S., Inc. | 6 | $479 |
| Sanofi-aventis U.S. LLC | 2 | $144 |
| Genentech USA, Inc. | 9 | $133 |
| Regeneron | 1 | $49 |
| Zimmer Biomet | 1 | $30 |
| Merck | 2 | $23 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Medexus Pharma, Inc. | 1 | $13 |
| Pacira Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,157,601 in reported general payments places this provider in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 35 | $289,749 |
| Humira(Cf) PenAdalimumab | 29 | $188,739 |
| LupkynisVoclosporin | 11 | $158,100 |
| RinvoqUpadacitinib | 15 | $144,512 |
| Xeljanz XrTofacitinib Citrate | 22 | $135,659 |
| RemicadeInfliximab | 14 | $120,260 |
| EnbrelEtanercept | 16 | $116,840 |
| OtezlaApremilast | 23 | $110,091 |
| KevzaraSarilumab | 14 | $95,888 |
| XeljanzTofacitinib Citrate | 17 | $95,051 |
| Taltz AutoinjectorIxekizumab | 11 | $74,854 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $60,542 |
| CellceptMycophenolate Mofetil | 14 | $30,430 |
| MethotrexateMethotrexate Sodium | 217 | $4,252 |
| Prednisone | 588 | $4,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $108,676 | $226,93139 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $479 | $158,10011 claims |
| AbbVieRinvoq | $179,106 | $144,51215 claims |
| Johnson & JohnsonRemicade | $61,404 | $120,26014 claims |
| SanofiKevzara | $198,915 | $95,88814 claims |
| PfizerXeljanz | $38,672 | $95,05117 claims |
| UCB, Inc.Cimzia (2 Pack) | $5,094 | $60,54211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Other rheumatology in Philadelphia
- Alexis Ogdie-BeattyPhiladelphia$433K
- Chris DerkPhiladelphia$66K
- Nora SandorfiPhiladelphia$52K
- Lawrence BrentPhiladelphia$22K
- Ethan CraigPhiladelphia$21K
- Monica LuchiPhiladelphia$20K
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.